Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
226.00
+1.97 (0.88%)
Oct 26, 2026, 9:38 AM EDT - Market open

Alnylam Pharmaceuticals Revenue

Alnylam Pharmaceuticals had revenue of $1.29B in the quarter ending June 30, 2026, with 66.86% growth. This brings the company's total for the last twelve months to $4.80B, up 95.14% year-over-year. In the year 2025, Alnylam Pharmaceuticals had annual revenue of $3.71B with 65.19% growth. That makes Alnylam Pharmaceuticals the 2,695th largest company in the world by revenue and 775th in the United States.

Revenue (ttm)
$4.80B
Revenue Growth
+95.14%
P/S Ratio
6.24
Revenue / Employee
$1,921,673
Employees
2,500
Market Cap
30.24B

Revenue Chart

Revenue by Segment

By Segment

Chart
  • AMVUTTRA 2.31B 62.3%
  • Roche - Collaboration 394.88M 10.6%
  • GIVLAARI 308.49M 8.3%
  • OXLUMO 191.44M 5.2%
  • Royalty 174.02M 4.7%
  • ONPATTRO 172.79M 4.7%
  • Regeneron Pharmaceuticals - Collaboration 113.96M 3.1%
  • Other - Collaboration 44.53M 1.2%

By Geography

  • United States 2.07B 69.2%
  • Europe 651.09M 21.8%
  • Rest of World 267.93M 9.0%
Fiscal year ended Dec 31, 2025 See the full Alnylam Pharmaceuticals breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20253.71B1.47B65.19%
Dec 31, 20242.25B419.95M22.97%
Dec 31, 20231.83B790.87M76.23%
Dec 31, 20221.04B193.13M22.88%
Dec 31, 2021844.29M351.43M71.31%
Dec 31, 2020492.85M273.10M124.28%
Dec 31, 2019219.75M144.84M193.36%
Dec 31, 201874.91M-15.00M-16.69%
Dec 31, 201789.91M42.75M90.66%
Dec 31, 201647.16M6.06M14.75%
Dec 31, 201541.10M-9.46M-18.72%
Dec 31, 201450.56M3.39M7.20%
Dec 31, 201347.17M-19.56M-29.31%
Dec 31, 201266.73M-16.03M-19.37%
Dec 31, 201182.76M-17.28M-17.28%
Dec 31, 2010100.04M-492.00K-0.49%
Dec 31, 2009100.53M4.37M4.54%
Dec 31, 200896.16M45.27M88.94%
Dec 31, 200750.90M23.97M89.00%
Dec 31, 200626.93M21.21M371.13%
Dec 31, 20055.72M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
BeOne Medicines AG6.13B
argenx SE5.92B
Incyte5.82B
Genmab4.13B
BioNTech SE3.03B
Royalty Pharma2.54B
Exelixis2.44B
Ascendis Pharma1.20B
Revenue Rankings